Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.

摘要: Abstract Objectives In the most of cases, for non-small cell lung cancer (NSCLC) patients who progressed to previous immune checkpoint inhibitors (CKI) administered as first- or second-line therapy, chemotherapy (CT) remains only viable options in absence “druggable” mutations. We aimed explore efficacy salvage after immunotherapy (SCAI) advanced NSCLC patients. Materials and Methods designed a retrospective, multicenter study, involving 20 Italian centers, with primary objective describing clinical outcome treated SCAI at participating institutions from November 2013 July 2019. The endpoint study was represented by overall survival (OS), defined time CT initiation death. Secondary endpoints (progression free survival, PFS, response rate, ORR toxicity) explorative biomarkers (lactate dehydrogenase, LDH, neutrophil-to-lymphocyte ratio, NLR during immunotherapy) were also analyzed. Results our population 342 patients, obtained median OS 6.8 months (95 % confidence interval, CI 5.5–8.1), PFS 4.1 3.4−4.8) 22.8 %. A “Post-CKI score” constructed combining significant predictors multivariate analyses (sex, ECOG PS, disease control prior immunotherapy), Harrell’C 0.65, CI:0.59−0.71). Conclusions Despite late-line settings, findings support hypothesis that might increase sensitivity tumor subsequent chemotherapy. clinically effective successfully discriminating three distinct prognostic subgroups failure CKI, representing possibly useful tool tailored decision-making process treatment-line settings NSCLC.